Upon joining the study, randomization occurs within 120 hours of hospital admission. This process assigns you to either the treatment group receiving high-dose pulse intravenous corticosteroid therapy or the standard therapy group.

If assigned to the treatment group, you will receive a medication called methylprednisolone sodium succinate through an intravenous infusion. This is a high-dose corticosteroid therapy aimed at reducing severe cardiac inflammation.

The infusion is administered in a hospital setting to ensure safety and monitor your response to the treatment.

Throughout the trial, your health will be closely monitored. This includes regular assessments of heart function using echocardiograms and other tests to measure heart-related biomarkers.

Your progress will be evaluated at various intervals, including after 3 days, 5 days, and 6 months from the start of the trial.

The primary outcome of the trial is to observe the time from randomization to the first occurrence of specific events such as all-cause death, heart transplant, or rehospitalization due to heart failure or arrhythmias within 6 months.

Secondary outcomes include measuring changes in heart function, such as left ventricular ejection fraction, and monitoring any reduction in heart rate or troponin levels, which are indicators of heart stress.

The trial is expected to conclude by December 31, 2028. Your participation will contribute to understanding the effectiveness and safety of the treatment for severe cardiac inflammation.